|Eligible Active Ingredient:||Triamcinolone acetonide. As a topical preparation as a single agent not exceeding 0.1%|
|With Effective From:||31-Mar-16|
|Indication Permitted:||Symptomatic relief of inflammatory skin or scalp disorders such as dermatitis and eczema.|
|Maximum Daily Dose:||Apply to the affected areas twice daily|
|Maximum Supply per Transaction:||15g for cream/ointment/gel;30ml for topical solution|
|Minimum Age of User:||18 years|
|Patient Information Leaflet from HSA/PSS:||Download PIL (Link to HSA website)|
Mechanism of Action of Triamcinolone acetonide
The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition of arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Firstly, however, these glucocorticoids bind to the glucocorticoid receptors which translocate into the nucleus and bind DNA (GRE) and change genetic expression both positively and negatively. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.
Additional Information of Triamcinolone acetonide
|Pharmacology Class:||Corticosteroids, Plain|
|Therapeutic Class:||Corticosteroids, Dermatological Preparations|
|Chemical Class:||Corticosteroids, Moderately Potent (Group II)|
|Synonyms:||11Œ≤,16Œ±,17Œ±,21-tetrahydroxy-9Œ±-fluoro-1,4-pregnadiene-3,20-dione | 9-fluoro-11Œ≤,16Œ±,17,21-tetrahydroxypregna-1,4-diene-3,20-dione | 9Œ±-fluoro-11Œ≤,16Œ±,17,21-tetrahydroxypregna-1,4-diene-3,20-dione | 9Œ±-fluoro-11Œ≤,16Œ±,17Œ±,21-tetrahydroxypregna-1,4-diene-3,20-dione | 9Œ±-fluoro-16Œ±-hydroxyprednisolone | Fluoxyprednisolone | Tiamcinolonum | Triamcinolona | Triamcinolonum|
Show All HSA-registered therapeutic products granted exemption to supply without prescription
HSA-Registered Products Containing Triamcinolone acetonide As a topical preparation as a single agent not exceeding 0.1%wpDataTable with provided ID not found!
This list is not exhaustive. HSA collaborates with Pharmaceurical Society of Singapore (PSS) to review the appropriate use of therapeutic products in the community from time to time. Hence, HSA may enable the supply of a Prescription Only Medicine (POM) by pharmacists without a prescription, upon review that the product can be used in a safe and effective manner under the supervision of a pharmacist. This can be effected through legislative mechanisms in the absence of an application made by the product registrant to reclassify the therapeutic product, subject to to conditions including indication, strength, maximum daily dose, maximum supply quantity, and age restriction.